LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.
复制标题
LateTIME：一项 II 期、随机、双盲、安慰剂对照试点试验，评估急性心肌梗塞后 2 至 3 周给予骨髓单核细胞的安全性和效果。
DOI：
--
复制
发表时间：
2010
影响因子：
0.9
通讯作者：
Forder,
中科院分区：
文献类型：
--
作者：
Traverse,JayH;Henry,TimothyD;Vaughan,DouglasE;Ellis,StephenG;Pepine,CarlJ;Willerson,JamesT;Zhao,DavidXM;Simpson,LaraM;Penn,MarcS;Byrne,BarryJ;Perin,EmersonC;Gee,AdrianP;Hatzopoulos,AntonisK;McKenna,DavidH;Forder,
